MOTS-c Preclinical

What It Is

MOTS-c (pronounced "mots-see") stands for "Mitochondrial Open Reading Frame of the Twelve S rRNA, type c." It is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) encoded by a small open reading frame within the mitochondrial 12S ribosomal RNA gene. Its discovery in 2015 by Changhan "David" Lee, Pinchas Cohen, and colleagues at the USC Leonard Davis School of Gerontology was a landmark finding for a conceptual reason as much as a therapeutic one: MOTS-c was among the first mitochondrial-derived peptides (MDPs) demonstrated to have systemic endocrine-like hormonal effects. Mitochondrial DNA had been understood to encode only a handful of proteins involved in local oxidative phosphorylation; MOTS-c extended the mitochondrial genome's role into peripheral metabolic signaling.

The mechanism-defining paper — Lee et al., Cell Metabolism 2015 (PMID 25738459) — demonstrated that MOTS-c regulates insulin sensitivity and metabolic homeostasis via AMPK activation mediated through inhibition of the folate cycle and de novo purine biosynthesis. That AMPK-activation framework places MOTS-c in the same functional category as metformin, AICAR, and caloric restriction — all of which converge on AMPK as a metabolic "energy sensor" that shifts cells toward fat oxidation, glucose uptake, and mitochondrial biogenesis.

The second landmark finding came in 2021 with Reynolds et al. in Nature Communications (PMID 33473109), showing that MOTS-c is induced by exercise in skeletal muscle and in circulation, and that exogenous MOTS-c administration improves age-dependent physical decline and muscle homeostasis in mice. Mice of all ages receiving MOTS-c injections performed significantly better than untreated controls on rotarod balance and treadmill endurance tests. This framing of MOTS-c as an "exercise-induced exercise mimetic" became the dominant narrative for the peptide in community and commercial contexts, alongside its insulin-sensitizing metabolic profile.

As of April 2026, there are no published Phase 2 or Phase 3 human randomized controlled trials for exogenous MOTS-c in any indication. The evidence base is rich preclinical data (mouse insulin sensitivity, muscle endurance, obesity, age-related physical decline) plus a growing observational human literature correlating endogenous MOTS-c levels with exercise response, insulin sensitivity, and age. Exogenous use in the community context is extrapolation from the preclinical framework, not from validated human outcomes.

Mechanism of Action

MOTS-c's mechanism is tightly centered on AMPK-mediated metabolic modulation, with secondary effects on mitochondrial biogenesis, inflammation, and exercise adaptation.

• AMPK activation via folate-cycle inhibition — MOTS-c inhibits the methylenetetrahydrofolate dehydrogenase-2 (MTHFD2)-dependent step of the folate cycle, reducing de novo purine biosynthesis and causing an AICAR (aminoimidazole carboxamide ribonucleotide) buildup that activates AMPK. Lee et al. 2015 established this as the primary mechanism.
• Skeletal muscle glucose uptake — Downstream of AMPK activation, MOTS-c increases GLUT4 translocation and glucose uptake into skeletal muscle independent of insulin — mechanistically similar to exercise-induced glucose uptake.
• Insulin sensitization — Mice administered MOTS-c showed improved insulin sensitivity and protection against high-fat-diet-induced insulin resistance. The effect is largest in skeletal muscle, the primary site of post-prandial glucose disposal.
• Mitochondrial biogenesis — AMPK-PGC-1α signaling downstream of MOTS-c promotes mitochondrial biogenesis and oxidative capacity in skeletal muscle.
• Fat oxidation — Shifts skeletal muscle substrate utilization toward fatty acid oxidation; reduces adiposity in high-fat diet mouse models.
• Exercise mimicry — Reynolds 2021 demonstrated that MOTS-c is induced in skeletal muscle by exercise (short-term) and in circulation (acute exercise bout response). Exogenous MOTS-c in sedentary mice produces exercise-like improvements in physical performance.
• Anti-inflammatory signaling — Reduces pro-inflammatory cytokine production in aged tissue models and attenuates obesity-associated inflammation.
• Nuclear translocation (unusual feature) — MOTS-c has been shown to translocate from mitochondria to the nucleus under metabolic stress, where it regulates adaptive gene expression programs. This is mechanistically unusual — most peptides act via cell-surface receptors rather than direct nuclear gene regulation.
• Bone metabolism — Emerging data suggest MOTS-c regulates osteoblast/osteoclast balance; bone density preservation in aged mouse models.
• Mitochondrial unfolded protein response (UPRmt) — Activates UPRmt, the mitochondrial quality control pathway associated with longevity in C. elegans models.
• Plasma-CNS distribution — MOTS-c crosses the blood-brain barrier in modest amounts; some CNS metabolic effects reported.

What the Research Shows

MOTS-c has an unusually rigorous preclinical evidence base for a community peptide, concentrated in the Lee/Cohen USC lab and independent replication groups.

• Discovery and metabolic characterization (Lee et al., Cell Metabolism 2015; PMID 25738459) — Foundational paper. Identified MOTS-c as mitochondrial-12S-rRNA-encoded, demonstrated AMPK-mediated insulin sensitization, prevented diet-induced insulin resistance in mice.
• Exercise-induced regulation (Reynolds et al., Nat Commun 2021; PMID 33473109) — Demonstrated MOTS-c is exercise-induced in skeletal muscle and circulation; exogenous MOTS-c restored age-dependent physical capacity in 2, 12, and 22-month-old mice.
• Insulin sensitizer review (D'Souza & Lamon, 2019; PMC6462348) — "MOTS-c: an equal opportunity insulin sensitizer" characterizing its broad effect across metabolic tissue types.
• Aging / age-related disease review (Ramanjaneya et al. 2022; PMID 36233287) — Modern comprehensive review of MOTS-c in aging and age-related diseases.
• Mitochondrial-derived peptides comprehensive review (Miller et al., Nat Rev Endocrinol 2020) — Placed MOTS-c in the broader MDP family (Humanin, SHLP1-6, MOTS-c) and mitochondrial-nuclear communication framework.
• Nuclear translocation under stress (Kim et al., Cell Metab 2018) — Established that MOTS-c translocates from mitochondria to nucleus under metabolic stress to regulate adaptive gene expression.
• Endurance and aging (Reynolds 2021 continuation) — In the flagship 2021 paper, MOTS-c more than doubled treadmill running capacity in untrained sedentary old mice — the specific data point that put "exercise protein" in the popular press.
• Human exercise response (Hyatt et al., Physiol Rep 2022) — Demonstrated MOTS-c elevation in human skeletal muscle after long-term physical activity; improved acute exercise performance in some trials.
• Ethnicity / breast cancer survivors — Effect of aerobic and resistance exercise on MOTS-c in Hispanic and non-Hispanic White breast cancer survivors (Sci Rep 2021) — documenting MOTS-c's responsiveness in human populations.
• Bone density / osteoporosis models — Preclinical data showing MOTS-c preserves bone mineral density in aged and ovariectomized mouse models.
• Cardiovascular / heart failure models — Preclinical protection against ischemia-reperfusion injury and cardiac hypertrophy.
• Adipose tissue metabolic modulation — Reduces adiposity, improves leptin sensitivity, increases brown adipose-like thermogenic activity in some models.
• Neuroprotection (Alzheimer's models) — Preclinical data showing reduced amyloid plaque burden and improved cognitive function in AD mouse models.

Human Data

Human data is primarily observational — correlating endogenous MOTS-c levels with physiology — rather than interventional exogenous MOTS-c administration:

• Age-related decline (observational, multiple studies) — Plasma MOTS-c declines with age in humans, paralleling mitochondrial function decline.
• Exercise-induced elevation (Reynolds 2021; Hyatt 2022) — Acute and chronic exercise raise plasma and skeletal muscle MOTS-c in humans.
• Insulin resistance correlation — Lower circulating MOTS-c in insulin-resistant and type 2 diabetic humans vs healthy controls.
• Breast cancer survivor exercise study (Sci Rep 2021) — Documents MOTS-c responsiveness to aerobic and resistance exercise in human cancer survivor population.
• Coronary artery disease correlation — Lower MOTS-c in patients with CAD; association is observational, not interventional.
• Menopause / sex differences — Differential MOTS-c in pre- vs post-menopausal women; observational.
• Community user reports — Anecdotal reports of improved endurance, insulin sensitivity, body composition on exogenous MOTS-c protocols; no validated outcome measures.
• No Phase 2 or Phase 3 RCT — As of April 2026, no exogenous MOTS-c human intervention trial has reached publication. This is the central evidence gap.

The situation parallels early NAD+ precursor research: strong mechanistic preclinical data, observational human biomarker correlation, but the decisive randomized controlled trial of exogenous administration lagging the commercial/community use. Over the next several years, published human MOTS-c RCT data will either confirm the mechanism translates to humans or force recalibration.

Dosing from the Literature

Absence of approved human dosing means all doses are either extrapolated from preclinical mouse data or drawn from community practice. Mouse studies commonly use 0.5 mg/kg IP daily.

Reconstitution & Storage

MOTS-c is supplied as lyophilized powder, typically 10 mg per vial.

• Reconstitution — Inject BAC water slowly down vial wall at 45°. Swirl gently; never shake. Clear colorless solution.
• Storage — Unreconstituted: 2–8°C preferred long-term. Reconstituted: 2–8°C, use within 21–28 days. Do not freeze reconstituted peptide.
• Injection sites — SubQ into abdomen (2" from navel) or thigh. Rotate sites.
• Timing — Pre-training dosing (30–60 min before workout) is common community practice based on the "exercise mimetic" framing. Morning fasted dosing is also common.
• Inspection — Discard if cloudy, discolored, or contaminated.

→ Use the Kalios Peptide Calculator for exact syringe units

Side Effects & Risks

MOTS-c has a generally favorable short-term safety profile in preclinical work, but long-term human safety data are absent.

• Injection site reactions — Mild, transient; typical SubQ peptide profile.
• Fatigue / initial lethargy — Some users report 1–3 days of fatigue on starting; may reflect metabolic adjustment.
• Hypoglycemia risk (theoretical) — AMPK activation and increased insulin sensitivity could produce hypoglycemia in diabetic users on insulin or secretagogues. Dose reduction of diabetic medications may be necessary.
• GI discomfort — Occasional mild nausea; usually mild.
• Appetite suppression — Some users report modest appetite reduction; helpful for body composition goals, inconvenient for muscle gain goals.
• Endurance improvement — Not an adverse effect, but users should be aware subjective training capacity changes can emerge, which affects overtraining risk if not monitored.
• Cancer caveat (theoretical) — AMPK activation is generally considered anti-proliferative (broadly protective), but any compound with broad gene-expression effects in aging pathways warrants caution in active malignancy.
• Autoimmune considerations — Minimal documented immune effects; chronic use in autoimmune conditions has not been rigorously studied.
• Drug interactions — Theoretical additive effects with metformin (both AMPK activators), with potential for stronger hypoglycemia. Consider dose reduction of diabetic medications with concurrent use.
• Pregnancy / lactation — Not studied; avoid.
• Purity / sourcing — Relatively newer peptide; synthesis quality varies. Third-party HPLC + mass spec COAs are the floor. 16-aa peptide is tractable synthesis; gross purity failures are less common than with larger peptides.
• WADA status — Not specifically listed on the WADA Prohibited List. As an exercise-mimetic mitochondrial peptide, athletes should consult their federation — broad umbrella categories (S4 metabolic modulators, S2 peptide hormones and related substances) could be applied.
• FDA status — Not approved; not a controlled substance. Gray-market research-chemical supply.

Supportive Nutrition & Supplements

MOTS-c is a metabolic modulator; its effects are amplified by complementary nutritional and lifestyle inputs that also activate AMPK or support mitochondrial function.

• Exercise (aerobic + resistance) — Directly synergistic with MOTS-c's exercise-mimetic mechanism. Training while on MOTS-c produces the largest combined effect in preclinical data.
• Time-restricted eating / intermittent fasting — Also activates AMPK endogenously. Compatible and complementary with MOTS-c protocol.
• Metformin (prescription) — Shares the AMPK-activation mechanism. Additive and occasionally used together in body-composition protocols, though the rationale for stacking two AMPK activators is debated.
• Caloric restriction — Most evidence-validated behavioral AMPK activator. Complements MOTS-c for metabolic endpoints.
• Protein (1.6–2.2 g/kg) — Supports lean mass during any metabolic protocol.
• Omega-3 (2–3 g EPA/DHA) — Mitochondrial membrane support; anti-inflammatory.
• Creatine monohydrate (3–5 g) — ATP buffering; complementary to mitochondrial capacity improvements.
• CoQ10 (100–200 mg) — Electron transport chain cofactor; complementary mitochondrial support.
• PQQ (20 mg) — Mitochondrial biogenesis cofactor; potentially complementary.
• B-complex — Folate cycle support. Given MOTS-c acts via folate-cycle inhibition, ensuring adequate methylfolate/B12 status prevents functional deficiency, though high-dose folate supplementation might theoretically attenuate MOTS-c's mechanism; middle-range B-vitamin status is prudent.
• Things to avoid — Chronic high-carbohydrate overconsumption (opposes the insulin-sensitization mechanism), chronic sleep restriction (blunts mitochondrial recovery), combining with insulin secretagogues without medical monitoring (hypoglycemia risk), chronic high alcohol (mitochondrial toxin).

What to Expect — Timeline

Individual response varies. Exogenous MOTS-c response patterns are still being characterized in humans; the following synthesizes available preclinical data and practitioner reports.

• Week 1 — Subtle; often no immediately noticeable subjective change. Some users report mild transient fatigue early. No body composition changes yet.
• Week 2–3 — Earliest reports of improved workout recovery, slight endurance improvement, modestly reduced appetite.
• Week 4–6 — Body composition changes emerge in responders — modest reduction in waist circumference, slight improvement in muscular endurance. Fasting glucose and fasting insulin improvements often measurable at 4 weeks.
• Week 6–12 — Plateau of metabolic benefits for responders. Insulin sensitivity improvements, body composition shifts, training capacity improvements accumulate.
• Post-cycle — Benefits reportedly persist for several weeks post-cycle, consistent with the gene-expression modulation framework. Full return to baseline typically within 1–3 months without continued use.
• Non-responders — Real. A substantial fraction of community users report no subjective change. Factors: product quality, training stimulus adequacy, baseline metabolic health, pharmacogenomic variation in mitochondrial biogenesis pathways.
• Exercise synergy — The largest subjective benefit is usually in combination with a structured training program. MOTS-c without training produces smaller effects than MOTS-c + training.
• Biomarker feedback — Fasting insulin, HbA1c, and DEXA body composition at baseline and 8–12 weeks provide the closest thing to objective response evaluation.
• If you feel worse — New hypoglycemia (if on diabetic medications), persistent fatigue, new mood changes, or any other new symptom — stop and evaluate.

Quick Compare — MOTS-c vs SS-31 vs NAD+ vs Humanin

MOTS-c sits in the "mitochondrial peptide / mitochondrial optimization" category. The most relevant comparators are other mitochondrial-targeting compounds — SS-31 (cardiolipin-binding), NAD+ precursors (substrate supply), and Humanin (another mitochondrial-derived peptide).

Practical interpretation:

• MOTS-c vs SS-31 — Different mitochondrial targets. MOTS-c activates AMPK systemically; SS-31 binds cardiolipin and stabilizes inner mitochondrial membrane. Complementary rather than substitutive.
• MOTS-c vs NAD+ — MOTS-c activates metabolic pathways; NAD+ provides substrate. Mechanism-complementary with no known antagonism; often stacked in "mitochondrial optimization" protocols.
• MOTS-c vs Humanin — Both mitochondrial-derived peptides. Humanin is more CNS-focused with documented neuroprotective effects; MOTS-c is more metabolic/peripheral. Combined "MDP stack" is community speculation rather than trial-validated.
• Evidence maturity — SS-31 is the only FDA-approved compound in this comparison (Barth syndrome, 2024). NAD+ precursors have the deepest supplement-level RCT base. MOTS-c has the strongest preclinical mechanistic evidence but thinnest human RCT data. Humanin is the least-developed clinically.
• Best fit — For systemic metabolic/body-comp goals with exercise synergy, MOTS-c is the mechanism-matched choice. For cardiac mitochondrial disease, SS-31. For broad longevity with cost/evidence balance, NAD+ precursors.

→ See full SS-31 profile  •  → See NAD+ profile  •  → See Humanin profile

Practical User Notes

• Combine with training — The dominant preclinical effect is exercise-synergistic. MOTS-c without training produces smaller effects. 2–4 structured training sessions per week is the practical floor for getting the mechanism-matched benefit.
• Start at 5 mg daily — Assess at 4 weeks. Escalate to 10 mg if needed based on biomarker and subjective response.
• Pre-training or morning dosing — Community practice favors 30–60 min pre-training or morning fasted dosing. No strong PK rationale for one over the other.
• Track biomarkers — Fasting insulin, HOMA-IR, HbA1c, DEXA body composition at baseline and 8–12 weeks. These give objective readouts where subjective response is unreliable.
• Cycle 8–12 weeks on / 4 weeks off — No documented tachyphylaxis, but cycling is conservative.
• Diabetic medication caution — If you are on insulin or insulin secretagogues, expect additional hypoglycemic effect. Dose reduction of diabetic medications may be necessary; work with your prescribing clinician.
• Don't stack multiple AMPK activators aggressively — MOTS-c + metformin + berberine + caloric restriction simultaneously is hypothetically additive but unstudied for safety. Start with one intervention and add one at a time.
• Injection technique — 29–31G insulin syringe, SubQ 45° into abdomen or thigh. Rotate sites.
• Sourcing — MOTS-c is a 16-aa peptide and tractable to synthesize, but newer in the research-chemical supply chain than older peptides. Independent third-party HPLC + mass spec COAs are the floor.
• Storage — Reconstituted solution 2–8°C; use within 28 days.
• Expect subtle benefits — Modest objective improvements in metabolic markers and endurance are realistic; dramatic transformation is not what the preclinical translation typically delivers.
• Red flags to stop — New hypoglycemia symptoms, persistent new fatigue, unusual mood changes, any new unexplained symptom. Cessation first, evaluation second.

Bloodwork & Monitoring

MOTS-c monitoring focuses on metabolic endpoints:

• Fasting insulin + HOMA-IR — The clearest direct-effect biomarker. Baseline and at 8–12 weeks.
• Fasting glucose + HbA1c — Baseline and quarterly during use.
• Lipid panel — Baseline and quarterly.
• CMP / CBC — Baseline and annually.
• hsCRP — Inflammation baseline; relevant given MOTS-c's anti-inflammatory signal.
• DEXA body composition — Baseline and at 12 weeks for objective fat-mass / lean-mass tracking.
• Plasma MOTS-c levels — Research/specialty assay; not routinely available clinically.
• VO2max or comparable fitness test — Baseline and at 12 weeks if endurance is a goal endpoint.
• Strength / performance metrics — Baseline objective performance tests (1-RM, grip strength) if muscle function is a goal.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching MOTS-c often also look at these:

Next Steps

Key References

1. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009.
2. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109. DOI: 10.1038/s41467-020-20790-0.
3. D'Souza RF, Lamon S. MOTS-c: an equal opportunity insulin sensitizer. J Mol Med (Berl). 2019;97(4):487-490. PMC6462348.
4. Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. PMID: 29983246.
5. Miller B, Kim SJ, Kumagai H, Mehta HH, Xiang W, Liu J, Yen K, Cohen P. Peptides derived from small mitochondrial open reading frames: Genomic, biochemical, and physiological features. Exp Cell Res. 2020;393(2):112057.
6. Ramanjaneya M, Jerobin J, Bettahi I, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(19):11991. PMID: 36233287.
7. Hyatt JK. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiol Rep. 2022;10(10):e15377.
8. Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med (Berl). 2019;97(4):473-485.
9. Mendelsohn AR, Larrick JW. Mitochondrial-Derived Peptides Exacerbate Senescence. Rejuvenation Res. 2018;21(4):369-373. PMID: 30037300.
10. Yin X, Jing Y, Chen Q, et al. The intraocular expression of MOTS-c in patients with age-related cataracts: Correlation between MOTS-c and lens mitochondrial DNA levels. Clin Exp Ophthalmol. 2022;50(5):498-506.
11. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717.
12. Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J Investig Med. 2018;66(6):1019-1022.
13. Kong BS, Lee C, Cho YM. Mitochondrial-encoded peptide MOTS-c, diabetes, and aging-related diseases. Diabetes Metab J. 2023;47(3):315-327. PMID: 36672073.
14. Yang B, Yu Q, Chang B, Guo Q, Xu S, Yi X, Cao S. MOTS-c interacts with mitochondrial proteins and exercise-induced adaptation. Biochem Biophys Res Commun. 2021;534:468-474.
15. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Sci Rep. 2021;11(1):16916.
16. Woodhead JST, D'Souza RF, Hedges CP, et al. High-intensity interval exercise increases humanin, a mitochondrial encoded peptide, in the plasma and muscle of men. J Appl Physiol. 2020;128(5):1346-1354.
17. Lee C, Yen K, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab. 2013;24(5):222-228. PMID: 23402768.
18. Kim SJ, Mehta HH, Wan J, Kuehnemann C, Chen J, Hu JF, Hoffman AR, Cohen P. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY). 2018;10(6):1239-1256.
19. Yen K, Mehta HH, Kim SJ, et al. The mitochondrial derived peptide Humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(12):11185-11199.
20. Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C, Liu L, Cui X. The mitochondrial-derived peptide MOTS-c promotes adipose tissue aging via inducing senescence of preadipocytes. Front Endocrinol. 2023;14:1120533. (Noting a published caveat — MDPs may have pro-senescence effects in some contexts.)